YUVA-GT-F901

Phase 1Biologic

SShenzhen Geno-Immune Medical Institute

YUVA-GT-F901 is one of 2 biologic programs targeting Hemophilia B. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemophilia BNot yet recruiting

Hemophilia BPhase 1

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Hemophilia B

#DrugCompanyPhaseTrials

BT200

BBand Therapeutics

Phase 3

1 2

YUVA-GT-F901

SShenzhen Geno-Immune Medical Institute

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

Hemophilia B

NCT03961243

Clinical

Trials by Indication[1]

Hemophilia B1 trial

Lentiviral FIX Gene Therapy for Hemophilia B

Not yet recruiting·SShenzhen Geno-Immune Medical Institute·Phase 1·NCT03961243·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for YUVA-GT-F901. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YUVA-GT-F901 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YUVA-GT-F901. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SShenzhen Geno-Immune Medical Institute

YUVA-GT-F901

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Hemophilia B1 trial

References

Drug Info

Quick Facts

Related News